title: First experience of effectiveness and safety of bedaquiline for 18 months within an optimised regimen for XDR-TB.
authors.affiliation: Tropical and Infectious Diseases Unit, Royal Liverpool University Hospital, Liverpool, UK Wellcome Trust Liverpool Glasgow Centre for Global Health Research, University of Liverpool, Liverpool, UK joseph.lewis@liverpool.ac.uk.
authors.forename: Joseph M
authors.initials: JM
authors.lastname: Lewis
authors.affiliation: Tropical and Infectious Diseases Unit, Royal Liverpool University Hospital, Liverpool, UK.
authors.forename: Paul
authors.initials: P
authors.lastname: Hine
authors.affiliation: Liverpool Community Health TB Services, Liverpool, UK.
authors.forename: Jenny
authors.initials: J
authors.lastname: Walker
authors.affiliation: Dept of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK.
authors.forename: Saye H
authors.initials: SH
authors.lastname: Khoo
authors.affiliation: Liverpool School of Tropical Medicine, Liverpool, UK.
authors.forename: Miriam
authors.initials: M
authors.lastname: Taegtmeyer
authors.affiliation: Liverpool School of Tropical Medicine, Liverpool, UK.
authors.forename: S Bertel
authors.initials: SB
authors.lastname: Squire
authors.affiliation: Liverpool School of Tropical Medicine, Liverpool, UK Liverpool Heart and Chest Hospital, Liverpool, UK.
authors.forename: Derek J
authors.initials: DJ
authors.lastname: Sloan
mesh_terms: D064687:Diarylquinolines / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D012449:Safety; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy*; D055815:Young Adult
chemical_list: D064687:Diarylquinolines; C493870:bedaquiline